Neal D. Shore

Neal D. Shore, MD, FACS is Medical Director of the Carolina Urologic Research Center and Chief Medical Officer of GenesisCare USA, with a faculty appointment at the Medical University of South Carolina. Dr. Shore is among the most prolific prostate cancer clinical trialists in community-based urology and oncology settings in the United States, having been a principal investigator or steering committee member in over 100 interventional clinical trials in genitourinary malignancies. He is best known for his central role in the ARCHES trial (JCO 2019), a phase III randomized study demonstrating that adding enzalutamide to androgen-deprivation therapy significantly reduced the risk of radiographic progression or death (HR 0.39; p<0.001) in metastatic hormone-sensitive prostate cancer, leading to FDA approval of enzalutamide for mHSPC in 2019. Dr. Shore also participated in the landmark PROSPER trial of enzalutamide in non-metastatic castration-resistant prostate cancer, was involved in early apalutamide (SPARTAN) investigations, and has led research on radium-223, denosumab, and other bone-targeted therapies in the mCRPC bone metastasis setting. His unique contribution has been bridging the gap between academic trial development and community practice implementation, ensuring that practice-changing trials include community oncology and urology sites and reflect real-world patient populations. Dr. Shore serves on multiple NCCN and AUA guideline committees and is a frequent author on prostate cancer treatment guidelines and patient decision-making.